Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:FTSV

Forty Seven (FTSV) Stock Price, News & Analysis

Forty Seven logo

About Forty Seven Stock (NASDAQ:FTSV)

Advanced Chart

Key Stats

Today's Range
$95.51
$95.51
50-Day Range
$95.51
$95.51
52-Week Range
$5.53
$95.51
Volume
N/A
Average Volume
1.61 million shs
Market Capitalization
$4.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive FTSV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Forty Seven and its competitors with MarketBeat's FREE daily newsletter.

FTSV Stock News Headlines

Janus Henderson Forty D
Google did what!?!?
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
Janus Henderson Forty T
Janus Henderson Forty S
See More Headlines

FTSV Stock Analysis - Frequently Asked Questions

Forty Seven Inc (NASDAQ:FTSV) posted its earnings results on Tuesday, November, 12th. The company reported ($0.38) EPS for the quarter, hitting analysts' consensus estimates of ($0.38). The firm had revenue of $15.68 million for the quarter, compared to analyst estimates of $15.80 million.

Forty Seven (FTSV) raised $100 million in an initial public offering on Thursday, June 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity, BTIG and Oppenheimer were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Forty Seven investors own include Gilead Sciences (GILD), TG Therapeutics (TGTX), Clovis Oncology (CLVS), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Abbott Laboratories (ABT) and ACADIA Pharmaceuticals (ACAD).

Company Calendar

Last Earnings
11/12/2019
Today
7/13/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FTSV
CIK
N/A
Fax
N/A
Employees
57
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($2.34)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$87.62 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-50.38%
Return on Assets
-44.35%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
14.81
Quick Ratio
14.81

Sales & Book Value

Annual Sales
$15.68 million
Price / Sales
293.33
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.52 per share
Price / Book
12.70

Miscellaneous

Outstanding Shares
48,156,000
Free Float
N/A
Market Cap
$4.60 billion
Optionable
Not Optionable
Beta
0.40
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:FTSV) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners